Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Opus Genetics (IRD) Change in Acquisitions & Divestments (2020)

Opus Genetics has reported Change in Acquisitions & Divestments over the past 3 years, most recently at $3.0 million for Q1 2020.

Quarterly Change in Acquisitions & Divestments changed N/A to $3.0 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2020, changed N/A year-over-year, with the annual reading at $12.0 million for FY2019, 0.42% changed from the prior year.
Change in Acquisitions & Divestments was $3.0 million for Q1 2020 at Opus Genetics, up from $1.8 million in the prior quarter.
Over five years, Change in Acquisitions & Divestments peaked at $3.0 million in Q1 2020 and troughed at $3.0 million in Q1 2020.